-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the internationally renowned academic journal "Bioactive Materials" (Bioactive Materials) published online the title of "Oxaliplatin-loaded nanoparticles for immunogenic chemotherapy and tumor antigen-specific immunotherapy" by Professor Wang Jianxin's team from the School of Pharmacy, Fudan University.
"Mature dendritic cell-derived dendrosomes swallow oxaliplatin-loaded nanoparticles to boost immunogenic chemotherapy and tumor antigen-specific immunotherapy"
.
This paper reports a dendritic cell (DC) biomimetic nanoformulation, which can participate in immunochemotherapy combination therapy, amplify the effect of tumor immune response, and have a significant anti-tumor effect
Immunotherapy based on DC whole-cell vaccines has been shown to be one of the most promising tumor treatments, however, cell therapy is accompanied by biosafety risks, insufficient antigen stimulation in the immune system, and immunosuppressive tumors during tumorigenesis and progression The formation of the microenvironment has led to very limited benefits in clinical applications
.
This study firstly used biomimetic nanocarrier technology to design and construct a tumor antigen self-presenting DC vesicle.
Schematic illustration of the interaction of NP/mDs with tumor and immune cells to remodel the local tumor microenvironment
Chen Xing, a 2018 doctoral student from the School of Pharmacy, Fudan University, is the first author of the paper, and Professor Wang Jianxin from the School of Pharmacy and Yin Bo, deputy chief physician of the Department of Radiology of Huashan Hospital, are the corresponding authors of the paper
.
This research was supported by the National Natural Science Foundation of China Major Project (81690263) and the National Natural Science Foundation of China General Project (81773911)
Original link: https://doi.
org/10.
1016/j.
bioactmat.
2021.
12.
020
Introduction of Wang Jianxin's research group
Professor Wang Jianxin's research group was established in 2005, mainly engaged in the construction of targeted drug delivery systems based on pathological characteristics, the research of oral drug delivery systems, and the development of new drug dosage forms and new preparations
.
It has trained 20 master students and 17 doctoral students, and currently has 5 master students and 12 doctoral students
Professor Wang Jianxin is currently a member of the National Drug Registration Review Expert Advisory Committee, a member of the Pharmacy Special Committee of the Chinese Pharmaceutical Association, a member of the Industrial Pharmacy Special Committee of the Chinese Pharmaceutical Association, and the Standing Committee of the New Drug Delivery System Professional Committee of the World Federation of Chinese Medicine Societies.
